🇺🇸 FDA
Patent

US 9550756

Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders

granted A61KA61K9/2059A61P

Quick answer

US patent 9550756 (Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders) held by Takeda Pharmaceutical Company Limited expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K9/2059, A61P, A61P25/00, A61P25/14